KellBenx Inc., a New York-based startup focused on developing a non-invasive DNA test that will analyze fetal cells that are intact within maternal blood samples as an alternative to traditional prenatal blood tests, has filed a statement with the Securities and Exchange Commission indicating its intent to raise $10 million in a securities offering. Founded in 2010 by CEO Hassan Bannani and President and Chair Leonard Kellner who both previously worked at a women’s health-focused lab, the company is also working on a breakthrough test to determine whether a woman is likely to deliver prematurely. See, July 22, 2013.